查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美肌少症治疗市场预测至 2030 年 - 区域分析 - 按治疗类型和配销通路
市场调查报告书
商品编码
1562379

北美肌少症治疗市场预测至 2030 年 - 区域分析 - 按治疗类型和配销通路

North America Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 72 Pages | 订单完成后即时交付

价格

2022年北美肌肉减少症治疗市场估值为14.5112亿美元，预计2030年将达到22.7385亿美元；预计2022年至2030年复合年增长率为5.8%。

老年人口激增推动北美肌少症治疗市场

老年人群容易出现肌少症、骨科疾病、代谢紊乱和神经系统疾病等。肌少症是一种老年疾病，其特征是骨骼肌质量和强度逐渐丧失。它与较高的不利健康结果风险有关，例如跌倒、残疾、收容、生活品质差和死亡。已开发国家的老年人口正在迅速增加。根据世界卫生组织(WHO) 的数据，到2050 年，全球老化人口可能会从2019 年的约10 亿增加到约21 亿。约1920年至2020年这100年间总人口成长速度快五倍。

老化导致肌肉量减少，这是身体组成的主要变化之一。老年人食物消耗的显着下降是导致肌肉量损失的关键因素之一。根据美国国家医学图书馆的数据，50-60岁年龄层的人每年损失近1.5%的肌肉力量，而60岁以后每年损失1-2%的肌肉量。肌肉少症盛行率较高。根据 Elsevier 2023 年 6 月发表的一篇文章，肌少症的盛行率从糖尿病患者的 18% 到无法治癒的食道癌患者的 66% 不等。因此，老年人口的增加对肌少症治疗市场的成长做出了重大贡献。

北美肌少症治疗市场概述

北美的肌少症治疗市场分为美国、加拿大和墨西哥。 2022 年，北美占据全球市场的最大份额。此外，随着老年人维生素 B12 和维生素 D 缺乏病例的增加，骨科疾病的盛行率激增，也推动了该地区的市场。

肌少症的盛行率因年龄和性别而异；居住在美国辅助生活设施或社区的老年人罹患这种疾病的风险较高。根据美国国立卫生研究院的数据，2019年美国肌肉减少症患者的预计住院费用为404亿美元。患有肌少症的人每年比肌肉量和功能正常的人多支付 2,315 美元的住院费用；他们住院的可能性几乎是没有肌少症的人的两倍。此外，骨骼肌损失减少 10% 可以预防肌少症可能的合併症，并为美国每年节省约 10 亿美元的医疗费用。

北美肌少症治疗市场收入及 2030 年预测（百万美元）

北美肌少症治疗市场区隔

北美肌少症治疗市场按治疗类型、配销通路和国家分类。

根据治疗类型，北美肌少症治疗市场分为维生素 D 和钙补充剂、蛋白质补充剂、维生素 B12 补充剂等。 2022 年，维生素 D 和钙补充剂领域占据北美肌少症治疗市场最大份额。

在配销通路方面，北美肌少症治疗市场分为药局、零售通路、线上通路等。 2022 年，药局部门占据北美肌少症治疗市场最大份额。

依国家/地区划分，北美肌少症治疗市场分为美国、加拿大和墨西哥。 2022 年，美国在北美肌少症治疗市场占有率中占据主导地位。

Abbott Laboratories、Bayer AG、Metagenics LLC、Nestle Health Science SA、Novartis AG、Pfizer Inc、Sanofi SA、Amway Corp、GSK Plc 和 Makers Nutrition LLC 是北美肌肉减少症治疗市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 主要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美肌少症治疗市场 - 主要产业动态

  • 北美肌少症治疗市场 - 主要产业动态
  • 市场驱动因素
    • 老年人口激增
    • 成人营养不良和维生素缺乏症增加
  • 主要市场限制：
    • 无法直接干预
  • 主要市场机会：
    • 处于临床试验阶段的产品
  • 未来趋势：
    • 人们对肌少症的认识不断提高
  • 驱动因素和限制的影响：

第 5 章：肌少症治疗市场 - 北美市场分析

  • 北美肌少症治疗市场收入，2020 - 2030
  • 北美肌少症治疗市场预测与分析

第 6 章：北美肌少症治疗市场分析 - 按治疗类型

  • 维生素 D 和钙补充剂
  • 蛋白质补充剂
  • 维生素 B12 补充剂
  • 其他的

第 7 章：北美肌少症治疗市场分析 - 按配销通路

  • 药局
  • 零售通路
  • 线上通路
  • 其他的

第 8 章：北美肌少症治疗市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 9 章：肌少症治疗市场-产业格局

  • 概述
  • 肌少症治疗市场的成长策略
  • 无机成长策略
    • 概述
  • 有机成长策略
    • 概述

第 10 章：公司简介

  • Abbott Laboratories
  • Bayer AG
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Amway Corp
  • GSK Plc
  • Makers Nutrition LLC

第 11 章：附录

Product Code: BMIRE00030523

The North America sarcopenia treatment market was valued at US$ 1,451.12 million in 2022 and is expected to reach US$ 2,273.85 million by 2030; it is estimated to register a CAGR of 5.8% from 2022 to 2030.

Upsurge in Geriatric Population Fuels North America Sarcopenia Treatment Market

The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. Also, according to the 2020 Census, the population of US 65 and older increased about five times faster than the total population during the 100 years between 1920 and 2020. In 2020, the number of older populations reached 55.8 million, or 16.8% of the total population of the US.

Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.

North America Sarcopenia Treatment Market Overview

The sarcopenia treatment market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest share of the global market in 2022. The sarcopenia treatment market growth in North America is attributed to the rising adoption of nutraceutical supplements for the treatment. In addition, the surging prevalence of orthopedic disorders with the increasing number of cases of vitamin B12 and vitamin D deficiency in the geriatric population fuels the market in this region.

Sarcopenia prevalence varies with age and gender; elderly people residing in assisted living facilities or communities in the US are at a higher risk of developing this condition. According to the National Institute of Health, in 2019, the anticipated hospitalization cost for persons with sarcopenia in the US was US$ 40.4 billion. People with sarcopenia pay US$ 2,315 more for hospital visits than people with normal muscle mass and function every year on average; they are almost twice as likely to be hospitalized than people without sarcopenia. Additionally, a 10% decrease in the loss of skeletal muscle can prevent the possible comorbidity of sarcopenia and save around US$ 1 billion in annual US medical care expenses.

North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

North America Sarcopenia Treatment Market Segmentation

The North America sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the North America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest North America sarcopenia treatment market share in 2022.

In terms of distribution channel, the North America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest North America sarcopenia treatment market share in 2022.

By country, the North America sarcopenia treatment market is segmented into the US, Canada, and Mexico. The US dominated the North America sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are some of the leading companies operating in the North America sarcopenia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Sarcopenia Treatment Market - Key Industry Dynamics

  • 4.1 North America Sarcopenia Treatment Market - Key Industry Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Upsurge in Geriatric Population
    • 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
  • 4.3 Key Market Restraints:
    • 4.3.1 Unavailability of Direct Interventions
  • 4.4 Key Market Opportunities:
    • 4.4.1 Products in Clinical Trial Phases
  • 4.5 Future Trends:
    • 4.5.1 Rising Awareness About Sarcopenia
  • 4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - North America Market Analysis

  • 5.1 North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • 5.2 North America Sarcopenia Treatment Market Forecast and Analysis

6. North America Sarcopenia Treatment Market Analysis - By Treatment Type

  • 6.1 Vitamin D and Calcium Supplement
    • 6.1.1 Overview
    • 6.1.2 Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.2 Protein Supplement
    • 6.2.1 Overview
    • 6.2.2 Protein Supplement : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Vitamin B12 Supplement
    • 6.3.1 Overview
    • 6.3.2 Vitamin B12 Supplement: North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. North America Sarcopenia Treatment Market Analysis - By Distribution Channel

  • 7.1 Pharmacies
    • 7.1.1 Overview
    • 7.1.2 Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Retail Channels
    • 7.2.1 Overview
    • 7.2.2 Retail Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Online Channels
    • 7.3.1 Overview
    • 7.3.2 Online Channels : North America Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others : North America Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. North America Sarcopenia Treatment Market - Country Analysis

  • 8.1 North America
    • 8.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.1 North America Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.2 United States Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.2.1 United States Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.2.2 United States Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.3 Canada Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.3.1 Canada Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.3.2 Canada Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.4 Mexico Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.4.1 Mexico Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.4.2 Mexico Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Sarcopenia Treatment Market
  • 9.3 Inorganic Growth Strategies
    • 9.3.1 Overview
  • 9.4 Organic Growth Strategies
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 Bayer AG
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Metagenics LLC
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Nestle Health Science SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Novartis AG
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Pfizer Inc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Sanofi SA
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Amway Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 GSK Plc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments
  • 10.10 Makers Nutrition LLC
    • 10.10.1 Key Facts
    • 10.10.2 Business Description
    • 10.10.3 Products and Services
    • 10.10.4 Financial Overview
    • 10.10.5 SWOT Analysis
    • 10.10.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms

List Of Tables

  • Table 1. North America Sarcopenia Treatment Market Segmentation
  • Table 2. Sarcopenia Drug Under Clinical Development
  • Table 3. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030 (US$ Million) - By Treatment Type
  • Table 5. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million) - By Distribution Channel
  • Table 6. North America Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Country
  • Table 7. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 8. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 9. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 10. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 11. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 12. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 13. Recent Inorganic Growth Strategies in the Sarcopenia Treatment Market
  • Table 14. Recent Organic Growth Strategies in the Sarcopenia Treatment Market
  • Table 15. Glossary of Terms, Sarcopenia Treatment Market

List Of Figures

  • Figure 1. North America Sarcopenia Treatment Market Segmentation, By Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. North America Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • Figure 4. North America Sarcopenia Treatment Market Share (%) - By Treatment Type, 2022 and 2030
  • Figure 5. Vitamin D and Calcium Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 6. Protein Supplement : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 7. Vitamin B12 Supplement: North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 8. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 9. North America Sarcopenia Treatment Market Share (%) - By Distribution Channel, 2022 and 2030
  • Figure 10. Pharmacies : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 11. Retail Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 12. Online Channels : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 13. Others : North America Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 14. North America Sarcopenia Treatment Market Revenue, by Key Countries, (2022) (US$ Mn)
  • Figure 15. North America Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 16. United States Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 17. Canada Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 18. Mexico Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 19. Growth Strategies in the Sarcopenia Treatment Market